Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer


Series C | Alive

Total Raised


About EuBiologics

Provider of vaccine for national prevention. The company develops bio-pharmaceuticals such as vaccines and protein medicines. It also offers customized commercialization services.

EuBiologics Headquarter Location

3rd Floor, BioVenture Plaza 56 Soyanggang-ro

Chuncheon, 24427,

South Korea

82 33 817 4001

Latest EuBiologics News

EuBiologics files for phase 3 study of homegrown COVID-19 vaccine

Oct 13, 2021

| Vials labelled "EuCOVAC-19" and syringes are seen in front of a displayed EuBiologics logo (EuBiologics) EuBiologics has asked for the Ministry of Food and Drug Safety’s approval on its plan to conduct a phase 3 clinical trial of its self-developed COVID-19 vaccine candidate, becoming the second South Korean company to reach that stage in the race to develop homegrown vaccines. According to the company’s regulatory filing on Wednesday, the clinical study of its vaccine candidate EuCorVac-19 will involve 4,000 participants. The safety and efficacy of the vaccine will be evaluated through comparison with the AstraZeneca vaccine, the company added. EuCorVac-19 is a recombinant protein vaccine made with genetic recombination technology. The surface antigen of the vaccine stimulates the immune cell to produce neutralizing antibodies to fight COVID-19. If approved, EuBiologics will become the second local company after SK Bioscience to commence a phase 3 clinical trial of a homegrown COVID-19 vaccine. The company plans to seek regulatory approvals for phase 3 clinical trials in foreign countries as well. In June, EuBiologics completed its phase 1 clinical study and started a phase 2 clinical trial for the vaccine candidate. The company said it has now finished administrating the drug candidate to 230 healthy adults. The release of the phase 2 study results is slated for November. Meanwhile, EuBiologics is adding a 1,000-liter culture line in the company’s second plant in Chuncheon, Gangwon Province. After the expansion, the company expects to have an annual manufacturing capacity of around 100 million to 200 million doses of EuCorVac-19. By Shim Woo-hyun ( )

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing EuBiologics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EuBiologics is included in 1 Expert Collection, including Biopharmaceuticals.



5,881 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

EuBiologics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

EuBiologics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.